GlassScriptPhysician profile
Breony Stoddard
NPI 1578711057
$2,610.36
in general payments reported to CMS, 2019-2025
36 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $794 · 2022: $731 · 2023: $329 · 2024: $117 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.58 | 2021-2025 | |
| Amgen INC. | $286.89 | 2021-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $168.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $147.34 | 2021-2025 | Veozah |
| Lilly USA, LLC | $136.66 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $101.03 | 2022-2024 | |
| Boston Scientific Corporation | $94.13 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $82.93 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $82.54 | 2021-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $75.81 | 2021-2025 | Farxiga |
| Inspire Medical Systems, INC. | $67.29 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $66.62 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $59.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.09 | 2021-2022 | |
| Amarin Pharma, INC. | $55.67 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $51.70 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $45.15 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $37.57 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.00 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $36.14 | 2022 | |
| Pfizer INC. | $33.39 | 2023-2025 | |
| Biogen, INC. | $32.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.65 | 2021-2022 | |
| Exact Sciences Corporation | $30.18 | 2023-2024 | Cologuard Collection Kit |
| Life Molecular Imaging LTD | $26.19 | 2025 | Neuraceq |
| Pacira Pharmaceuticals Incorporated | $25.81 | 2024 | Zilretta |
| Rgh Enterprises LLC | $25.00 | 2025 | |
| Sumitomo Pharma America, INC. | $24.10 | 2023 | Gemtesa |
| Alkermes, INC. | $20.67 | 2023 | Lybalvi |
| Almatica Pharma LLC | $17.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.61 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.43 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.39 | 2025 | Edarbyclor |
| Eisai INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breony Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.